{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:02:47Z","timestamp":1775610167851,"version":"3.50.1"},"reference-count":90,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Breast cancer remains a significant contributor to morbidity and mortality within oncology. Risk factors, encompassing genetic and environmental influences, significantly contribute to its prevalence. While germline mutations, notably within the BRCA genes, are commonly associated with heightened breast cancer risk, a spectrum of other variants exists among affected individuals. Diagnosis relies on imaging techniques, biopsies, biomarkers, and genetic testing, facilitating personalised risk assessment through specific scoring systems. Breast cancer screening programs employing mammography and other imaging modalities play a crucial role in early detection and management, leading to improved outcomes for affected individuals. Regular screening enables the identification of suspicious lesions or abnormalities at earlier stages, facilitating timely intervention and potentially reducing mortality rates associated with breast cancer. Genetic mutations guide screening protocols, prophylactic interventions, treatment modalities, and patient prognosis. Prophylactic measures encompass a range of interventions, including chemoprevention, hormonal inhibition, oophorectomy, and mastectomy. Despite their efficacy in mitigating breast cancer incidence, these interventions carry potential side effects and psychological implications, necessitating comprehensive counselling tailored to individual cases.<\/jats:p>","DOI":"10.3390\/medicina60040570","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:44:52Z","timestamp":1711892692000},"page":"570","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Breast Cancer Screening and Prophylactic Mastectomy for High-Risk Women in Romania"],"prefix":"10.3390","volume":"60","author":[{"given":"Claudiu Ioan","family":"Filip","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery and Burn Unit, Emergency District Hospital, 400535 Cluj-Napoca, Romania"},{"name":"First Surgical Clinic, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"C\u0103tan\u0103","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"},{"name":"Department of Oncogeneticcs, Institute of Oncology, \u201cProf. Dr. I. Chiricu\u021b\u0103\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Regional Laboratory Cluj-Napoca, Department of Medical Genetics, Regina Maria Health Network, 400363 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-3246","authenticated-orcid":false,"given":"Eniko","family":"Kutasi","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5856-1487","authenticated-orcid":false,"given":"Sara Alexia","family":"Roman","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela Sanda","family":"Militaru","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"},{"name":"Regional Laboratory Cluj-Napoca, Department of Medical Genetics, Regina Maria Health Network, 400363 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4313-9611","authenticated-orcid":false,"given":"Giulia Andreea","family":"Risteiu","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George C\u0103lin","family":"Dindelengan","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery and Burn Unit, Emergency District Hospital, 400535 Cluj-Napoca, Romania"},{"name":"First Surgical Clinic, Faculty of Medicine, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"ref_1","unstructured":"(2024, February 07). Breast Cancer [Internet]. World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trecan.2020.01.007","article-title":"TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines","volume":"6","author":"Shahbandi","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i1504","DOI":"10.1136\/bmj.i1504","article-title":"Rates of prophylactic mastectomy triple in decade, study shows","volume":"352","author":"Wise","year":"2016","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","unstructured":"World Health Organization (2018). Global Health Estimates 2016: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000\u20132016, World Health Organization. Available online: https:\/\/www.who.int\/data\/global-health-estimates."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.321.7261.624","article-title":"ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics","volume":"321","author":"McPherson","year":"2000","journal-title":"BJM"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.18632\/aging.202502","article-title":"Global incidence and mortality of breast cancer: A trend analysis","volume":"13","author":"Huang","year":"2021","journal-title":"Aging"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kashyap, D., Pal, D., Sharma, R., Garg, V.K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., and Belay, A. (2022). Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/9605439"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3892\/etm.2021.9699","article-title":"Breast cancer mortality gaps in Romanian women compared to the EU after 10 years of accession: Is breast cancer screening a priority for action in Romania? (Review of the Statistics)","volume":"21","author":"Furtunescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01926","DOI":"10.7554\/eLife.01926","article-title":"Targeting the link between late pregnancy and breast cancer","volume":"2","author":"Chakravarthi","year":"2013","journal-title":"Elife"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1055-9965.EPI-17-0531","article-title":"Emerging Trends in Family History of Breast Cancer and Associated Risk","volume":"26","author":"Shiyanbola","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"740227","DOI":"10.3389\/fonc.2021.740227","article-title":"Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population","volume":"11","author":"Shen","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/onc.2015.181","article-title":"Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations","volume":"35","author":"Golmard","year":"2016","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1038\/s41598-021-85899-8","article-title":"Correlation between family history and characteristics of breast cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-020-01260-3","article-title":"Clinical applications of polygenic breast cancer risk: A critical review and perspectives of an emerging field","volume":"22","author":"Yanes","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_16","first-page":"445","article-title":"BRCA1 and BRCA2 mutations and breast cancer","volume":"12","author":"Narod","year":"2011","journal-title":"Discov. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Torabi Dalivandan, S., Plummer, J., and Gayther, S.A. (2021). Risks and Function of Breast Cancer Susceptibility Alleles. Cancers, 13.","DOI":"10.3390\/cancers13163953"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Clark, S.L., Rodriguez, A.M., Snyder, R.R., Hankins, G.D.V., and Boehning, D. (2012). Structure-Function of the Tumor Suppressor BRCA1. Comput. Struct. Biotechnol. J., 1.","DOI":"10.5936\/csbj.201204005"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32931","DOI":"10.1074\/jbc.274.46.32931","article-title":"Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G2\/M checkpoint control","volume":"274","author":"Chen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1758835920975326","DOI":"10.1177\/1758835920975326","article-title":"BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: Genotype-phenotype correlation in a cohort of 531 patients","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2147\/OTT.S369844","article-title":"Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants","volume":"15","author":"Edaily","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02982016","article-title":"Molecular pathogenesis of Fanconi anemia","volume":"75","author":"Taniguchi","year":"2002","journal-title":"Int. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 Pathogenic variants: An international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e7747","DOI":"10.1002\/ccr3.7747","article-title":"Management of PALB2-associated breast cancer: A literature review and case report","volume":"11","author":"Toss","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djac188","article-title":"Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome","volume":"115","author":"Hendricks","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","article-title":"Breast cancer risk and clinical implications for germline PTEN mutation carriers","volume":"165","author":"Ngeow","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Corso, G., Montagna, G., Figueiredo, J., La Vecchia, C., Romario, U.F., Fernandes, M.S., Seixas, S., Roviello, F., Trovato, C., and Guerini-Rocco, E. (2020). Hereditary gastric and breast cancer syndromes related to CDH1 germline mutation: A multidisciplinary clinical review. Cancers, 12.","DOI":"10.3390\/cancers12061598"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CEJ.0000000000000405","article-title":"Prognosis and outcome in CDH1-mutant lobular breast cancer","volume":"27","author":"Corso","year":"2018","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline Pathogenic Variants in the Ataxia telangiectasia Mutated (ATM) Gene Are Associated with High and Moderate Risks for Multiple Cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Stucci, L.S., Intern\u00f2, V., Tucci, M., Perrone, M., Mannavola, F., Palmirotta, R., and Porta, C. (2021). The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes, 12.","DOI":"10.3390\/genes12050727"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"C\u0103tan\u0103, A., Trifa, A.P., Achimas-Cadariu, P.A., Bolba-Morar, G., Lisencu, C., Kutasi, E., Chelaru, V.F., Muntean, M., Martin, D.L., and Antone, N.Z. (2024). Hereditary Breast Cancer in Romania-Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051386"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2007.09.001","article-title":"Impact of aging on the biology of breast cancer","volume":"66","author":"Benz","year":"2008","journal-title":"Crit. Rev. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-023-01636-1","article-title":"Modifiable risk factors in women at high risk of breast cancer: A systematic review","volume":"25","author":"Cohen","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/aje\/kww145","article-title":"Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer","volume":"184","author":"Tamimi","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","article-title":"The Endogenous Hormones and Breast Cancer Collaborative Group Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies","volume":"94","author":"Key","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10549-012-2391-z","article-title":"Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up","volume":"137","author":"Zhang","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13058-018-0947-5","article-title":"Assessment of performance of the Gail model for predicting breast cancer risk: A systematic review and meta-analysis with trial sequential analysis","volume":"20","author":"Wang","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/1940-6207.CAPR-22-0460","article-title":"Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population","volume":"16","author":"Spaeth","year":"2023","journal-title":"Cancer Prev. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18760","DOI":"10.1038\/s41598-023-45402-x","article-title":"Breast Density Analysis Using Digital Breast Tomosynthesis","volume":"13","author":"Heine","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.10.022","article-title":"Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer","volume":"88","author":"Duffy","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.breast.2022.04.003","article-title":"Global guidelines for breast cancer screening: A systematic review","volume":"64","author":"Ren","year":"2022","journal-title":"Breast"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.7314\/APJCP.2014.15.16.6525","article-title":"Health beliefs and breast self-examination among female university nursing students in Turkey","volume":"15","author":"Erbil","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_48","unstructured":"Esmo (2024, February 07). ESMO Clinical Practice Guidelines: Breast Cancer [Internet]. Available online: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/breast-cancer."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tang, S.N., Zuber, V., and Tsilidis, K.K. (2022). Identifying and ranking causal biochemical biomarkers for breast cancer: A Mendelian randomization study. BMC Med., 20.","DOI":"10.1186\/s12916-022-02660-2"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wu, H.J., and Chu, P.Y. (2021). Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020636"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.breast.2020.05.005","article-title":"Clinical utility of tumor marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance","volume":"52","author":"Hing","year":"2020","journal-title":"Breast"},{"key":"ref_52","first-page":"49","article-title":"Attitudes to and practice of breast and cervical cancer screening in Romania","volume":"2","author":"Cornelia","year":"2011","journal-title":"Int. J. Collab. Res. Intern. Med. Public Health"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1245\/s10434-015-4715-9","article-title":"Chemoprevention for Breast Cancer","volume":"22","author":"Pruthi","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ypmed.2019.105834","article-title":"Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians","volume":"129","author":"Ball","year":"2019","journal-title":"Prev. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the national surgical adjuvant breast and bowel project Study of tamoxifen and raloxifene (STAR) P-2 trial: Preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-017-4292-7","article-title":"A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen","volume":"165","author":"Thomson","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomized placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"40389","DOI":"10.18632\/oncotarget.16315","article-title":"Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mnfr.201400515","article-title":"Breast cancer chemoprevention by dietary natural phenolic compounds: Specific epigenetic related molecular targets","volume":"59","author":"Pan","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"75575","DOI":"10.1039\/C5RA14925H","article-title":"Recent advances of curcumin and its analogues in breast cancer prevention and treatment","volume":"5","author":"Mock","year":"2015","journal-title":"RSC Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/nutrit\/nuw010","article-title":"Chemopreventive properties of 3,3\u2019-diindolylmethane in breast cancer: Evidence from experimental and human studies","volume":"74","author":"Thomson","year":"2016","journal-title":"Nutr. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00520","DOI":"10.34172\/jrhs.2021.57","article-title":"Factors for the primary prevention of breast cancer: A meta-analysis of prospective cohort studies","volume":"21","author":"Poorolajal","year":"2021","journal-title":"J. Res. Health Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bertozzi, S., Londero, A.P., Xholli, A., Azioni, G., Di Vora, R., Paudice, M., Bucimazza, I., Cedolini, C., and Cagnacci, A. (2024). Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041422"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamaoncol.2021.2040","article-title":"Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic Variants","volume":"7","author":"Choi","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/1471-0528.16424","article-title":"Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: A cohort study","volume":"128","author":"Gaba","year":"2021","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2217\/fon-2017-0415","article-title":"Fertility preservation in BRCA-mutated women: When and how?","volume":"14","author":"Grynberg","year":"2018","journal-title":"Future Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ejso.2022.04.024","article-title":"Surgical management of BRCA-mutation carriers: A single institution experience","volume":"48","author":"Gentile","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/tbj.12352","article-title":"Breast cancer prevention","volume":"21","author":"Euhus","year":"2015","journal-title":"Breast J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1072-7515(00)00361-6","article-title":"Prophylactic mastectomy","volume":"191","author":"Newman","year":"2000","journal-title":"J. Am. Coll. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5152\/tjbh.2015.2520","article-title":"Endoscopy assisted oncoplastic breast surgery (EAOBS)","volume":"11","author":"Soybir","year":"2015","journal-title":"J. Breast Health"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bjs.6463","article-title":"Prophylactic mastectomy and the timing of breast reconstruction","volume":"96","author":"Morrow","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bjs.9884","article-title":"Nipple-sparing mastectomy in patients with BRCA1\/2 mutations and variants of uncertain significance","volume":"102","author":"Manning","year":"2015","journal-title":"Br. J. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","article-title":"Contralateral prophylactic mastectomy (CPM) consensus statement from the American society of breast surgeons: Data on CPM outcomes and risks","volume":"23","author":"Boughey","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02194-2","article-title":"Contralateral risk-reducing local therapy in breast cancer patients with BRCA1\/2 mutations: Systemic review and meta-analysis","volume":"21","author":"Jia","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijsu.2017.12.022","article-title":"Mastectomy for risk reduction or symmetry in women without high risk gene mutation: A review","volume":"50","author":"Kenny","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10434-999-0542-1","article-title":"Issues of regret in women with contralateral prophylactic mastectomies","volume":"6","author":"Montgomery","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ajm.AJM_21_18","article-title":"Prophylactic mastectomy for the prevention of breast cancer: Review of the literature","volume":"8","author":"Alaofi","year":"2018","journal-title":"Avicenna J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1200\/JCO.2005.09.233","article-title":"Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance","volume":"23","author":"Frost","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.breast.2010.05.003","article-title":"Bilateral prophylactic mastectomy in women with inherited risk of breast cancer\u2013prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery","volume":"19","author":"Gahm","year":"2010","journal-title":"Breast"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1245\/s10434-011-1917-7","article-title":"Contralateral prophylactic mastectomy: Long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits","volume":"18","author":"Frost","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jama.284.3.319","article-title":"Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy","volume":"284","author":"Frost","year":"2000","journal-title":"JAMA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10689-012-9588-5","article-title":"Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer","volume":"12","author":"Gopie","year":"2013","journal-title":"Fam. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"V\u00e2lcu, E.G., Firescu, D., Nechita, A., Ciubar\u0103, A., Constantin, G.B., Rahnea-Nita, G., and Rebegea, L.F. (2024). Considerations Regarding Online Group Psychotherapy Sessions for Breast Cancer Patients in Active Phase of Oncological Treatment. Healthcare, 11.","DOI":"10.3390\/healthcare11162311"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/4\/570\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:21:24Z","timestamp":1760106084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/4\/570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":90,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["medicina60040570"],"URL":"https:\/\/doi.org\/10.3390\/medicina60040570","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]}}}